PE20081400A1 - Sintesis de compuestos de pirrolidina - Google Patents

Sintesis de compuestos de pirrolidina

Info

Publication number
PE20081400A1
PE20081400A1 PE2008000034A PE2008000034A PE20081400A1 PE 20081400 A1 PE20081400 A1 PE 20081400A1 PE 2008000034 A PE2008000034 A PE 2008000034A PE 2008000034 A PE2008000034 A PE 2008000034A PE 20081400 A1 PE20081400 A1 PE 20081400A1
Authority
PE
Peru
Prior art keywords
alkyl
compound
formula
aryl
iii
Prior art date
Application number
PE2008000034A
Other languages
English (en)
Inventor
Asaf Ragim Alimardanov
Lalitha Krishnan
Maotang Zhou
Ting-Zhong Wang
Jianxin Ren
John L Considine
Charles C Wu
Jason Brazzillo
Panolil Raveendranath
Karen Sutherland
Mahmoud Mirmehrabi
Subodh Deshmukh
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081400A1 publication Critical patent/PE20081400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, ALQUILO(C1-C6) O C(O)R5, EN DONDE R5 ES ARILO(C6-C10), ALQUILO(C1-C20), CICLOALQUILO(C3-C10), ENTRE OTROS; W ES ALQUILENO(C1-C6); R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6), C(O)OR6 O C(O)R9, EN DONDE R6 ES ALQUILO(C1-C20); R9 ES H, ARILO(C6-C10), ALQUILO(C1-C20), ENTRE OTROS; EL CUAL COMPRENDE: A) HACER REACCIONAR UN COMPUESTO DE FORMULA (II) CON UN COMPUESTO DE FORMULA (IV) EN PRESENCIA DE UN AGENTE DE ACOPLAMIENTO TAL COMO DICICLOHEXILCARBODIIMIDA Y UN RESTO HIDROXILADO TAL COMO N-HIDROXIBENZOTRIAZOL PARA OBTENER UN COMPUESTO DE FORMULA (III) DONDE R7 ES H O ALQUILO(C1-C6); B) HACER REACCIONAR EL COMPUESTO DE FORMULA (III) CON UN HIDROXIDO DE METAL TAL COMO NaOH, KOH O LiOH EN PRESENCIA DE UN DISOLVENTE TAL COMO UNA MEZCLA DE AGUA Y ALCOHOL(C1-C3) A UNA TEMPERATURA DE -10ºC A 5ºC PARA OBTENER EL COMPUESTO DE FORMULA (I). ES UN COMPUESTO PREFERIDO: HIDROCLORURO DEL ACIDO (2S,4R)-1-(2-AMINOACETIL)-4-BENZAMIDOPIRROLIDINA-2-CARBOXILICO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS, INCONTINENCIA DE VEJIGA, DIABETES, ATEROSCLEROSIS
PE2008000034A 2006-12-21 2008-01-02 Sintesis de compuestos de pirrolidina PE20081400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87629006P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
PE20081400A1 true PE20081400A1 (es) 2008-10-24

Family

ID=39470360

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000034A PE20081400A1 (es) 2006-12-21 2008-01-02 Sintesis de compuestos de pirrolidina

Country Status (9)

Country Link
US (4) US20080188545A1 (es)
EP (2) EP2468724B1 (es)
AR (1) AR064626A1 (es)
DK (1) DK2468724T3 (es)
ES (1) ES2558856T3 (es)
PE (1) PE20081400A1 (es)
PL (1) PL2468724T3 (es)
TW (1) TW200833660A (es)
WO (1) WO2008079266A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443242T3 (es) 2005-12-23 2014-02-18 Zealand Pharma A/S Compuestos modificados miméticos de lisina
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
CN101863817A (zh) * 2009-06-09 2010-10-20 大连凯飞精细化工有限公司 (2s,4r)-4-氨基吡咯啉-1,2-二羧酸-1-叔丁酯-2-甲酯盐酸盐的制法
CN103333094B (zh) * 2013-06-19 2015-05-13 广东肇庆星湖生物科技股份有限公司 一种脯氨酸结晶精制的工艺方法
EP3618847B1 (en) 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
CN112142823B (zh) * 2019-06-28 2022-08-05 深圳翰宇药业股份有限公司 一种zp-1609的合成方法
EP3904339A1 (en) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Alkylaminoproline derivatives as alfa-2-delta-1 blockers
EP4291178A1 (en) 2021-02-10 2023-12-20 Breye Therapeutics ApS Danegaptide for use in the treatment or prevention of a kidney disease
CA3240515A1 (en) 2021-12-22 2023-06-29 Breye Therapeutics Aps Gap junction modulators and their use for the treatment of age-related macular degeneration

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5784223A (en) 1980-11-13 1982-05-26 Nissan Motor Co Ltd Vibration absorber of vehicle
US4462943A (en) 1980-11-24 1984-07-31 E. R. Squibb & Sons, Inc. Carboxyalkyl amino acid derivatives of various substituted prolines
ATE22692T1 (de) 1981-08-03 1986-10-15 Squibb & Sons Inc Phosphonamidate verbindungen.
US4514391A (en) 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
US4560506A (en) 1984-05-25 1985-12-24 E. R. Squibb & Sons, Inc. Mercaptocycloalkylcarbonyl and mercaptoarylcarbonyl dipeptides
ATE135711T1 (de) * 1984-09-12 1996-04-15 Rhone Poulenc Rorer Pharma Antihypertensive derivate
JPS61148198A (ja) * 1984-12-22 1986-07-05 Ajinomoto Co Inc 新規トリペプチド化合物および甘味剤
EP0566157A1 (en) 1986-06-20 1993-10-20 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4849525A (en) * 1987-09-21 1989-07-18 E. R. Squibb & Sons, Inc. Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
FR2700166B1 (fr) * 1993-01-07 1995-02-17 Rhone Poulenc Rorer Sa Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
AU1172995A (en) 1993-11-09 1995-05-29 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
DE4408531A1 (de) 1994-03-14 1995-09-28 Hoechst Ag PNA-Synthese unter Verwendung einer gegen schwache Säuren labilen Amino-Schutzgruppe
US5491164A (en) 1994-09-29 1996-02-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
AU5599898A (en) 1996-12-12 1998-07-03 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
DE69836386T2 (de) 1997-08-22 2007-10-11 Kaken Pharmaceutical Co., Ltd. Amide zur Förderung der Ausschüttung von Wachstumshormonen
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
MXPA02000888A (es) 1999-07-28 2002-07-30 Aventis Pharm Prod Inc Compuestos de oxoazaheterociclilos substituidos.
IL148972A0 (en) 1999-10-14 2002-11-10 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2001034594A1 (en) 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
AU781674B2 (en) 2000-02-23 2005-06-02 Zealand Pharma A/S Novel antiarrhythmic peptides
WO2002077017A2 (en) 2001-02-22 2002-10-03 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
AU2001251147A1 (en) 2000-03-31 2001-10-15 Dupont Pharmaceuticals Company Succinoylamino heterocycles as inhibitors of abeta protein production
EP1276717A2 (en) 2000-04-17 2003-01-22 Idun Pharmaceuticals, Inc. Inhibitors of the ice/ced-3 family of cysteine proteases
WO2001083517A1 (en) 2000-05-03 2001-11-08 Tularik Inc. Stat4 and stat6 binding dipeptide derivatives
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
DK1387674T3 (en) 2000-10-13 2017-04-10 Curis Inc Hedgehog antagonists, methods and uses related thereto
FR2816838B1 (fr) * 2000-11-17 2004-12-03 Oreal Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
EP1467989B1 (en) 2002-01-23 2009-09-23 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection
CA2475653A1 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
PL372826A1 (en) * 2002-07-26 2005-08-08 Altana Pharma Ag Pyrrolidine derivatives as tryptase inhibitors
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
MXPA05010444A (es) 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
EP1622870A2 (en) 2003-05-05 2006-02-08 Prosidion Ltd. Glutaminyl based dp iv-inhibitors
SI21507A (sl) * 2003-05-16 2004-12-31 LEK farmacevtska dru�ba d.d. Postopek za pripravo spojin z ace inhibitornim delovanjem
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
CN1528745A (zh) 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
WO2005085197A1 (en) 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
ME02221B (me) * 2004-03-15 2016-02-20 Janssen Pharmaceutica Nv Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
ES2443242T3 (es) * 2005-12-23 2014-02-18 Zealand Pharma A/S Compuestos modificados miméticos de lisina
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych

Also Published As

Publication number Publication date
EP2468724A1 (en) 2012-06-27
EP2468724B1 (en) 2015-11-18
EP2074087A2 (en) 2009-07-01
US20080188545A1 (en) 2008-08-07
US8927590B2 (en) 2015-01-06
US9469609B2 (en) 2016-10-18
ES2558856T3 (es) 2016-02-09
DK2468724T3 (en) 2016-02-22
US20130053344A1 (en) 2013-02-28
TW200833660A (en) 2008-08-16
WO2008079266A2 (en) 2008-07-03
WO2008079266A3 (en) 2008-11-06
AR064626A1 (es) 2009-04-15
US20150322007A1 (en) 2015-11-12
PL2468724T3 (pl) 2016-05-31
US20100249207A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
PE20081400A1 (es) Sintesis de compuestos de pirrolidina
US8143427B2 (en) Method for producing aminoacetylpyrrolidinecarbonitrile derivative
PE20081387A1 (es) Proceso de preparacion del acido 1-(2-etil-butil)-ciclohexanocarboxilico
EA201270550A1 (ru) Процесс получения соединений для применения в качестве ингибиторов sglt2
CO6382182A2 (es) Proceso para la preparación de benzonorbornen-5-il-amidas del ácido pirazolil-4-carboxílico.
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
AR055993A1 (es) Proceso para producir 3-oxo-pregnano-21,17-carbolactonas, asi como 3-oxo-pregn-4-eno-21,17-carbolactonas por oxidacion del correspondiente 17-(3-hidroxipropil)-3,17-dihidroxiandrostano
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR055057A1 (es) Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria.
TW200736221A (en) Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor
PE20100487A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
ES2421537T3 (es) Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
UY30387A1 (es) Nuevos compuestos
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
PE20090758A1 (es) Un proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina, utiles como intermediarios para florfenicol
AR063415A1 (es) Hidratos de clorhidrato de erlotinib para el tratamiento del cancer
PE20091401A1 (es) Procedimientos para preparar eteres aromaticos
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
AR083399A1 (es) Proceso para la preparacion de cicloheptapiridina como antagonista del receptor de cgrp
AR069319A1 (es) Metodo para preparar capecitabina y compuesto intermediario de trialquil carbonato.
PE20090602A1 (es) Nuevos compuestos
RU2011124888A (ru) Способ получения йодированного контрастного агента
JP2009114127A (ja) アミノアセチルピロリジンカルボニトリル誘導体の製造方法
AR064421A1 (es) Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento.

Legal Events

Date Code Title Description
FX Voluntary withdrawal